FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours ner response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MITCHELL DEAN J				2. Issuer Name and Ticker or Trading Symbol ImmunoGen, Inc. [IMGN]						(Ch	eck all applic	or		10% Owner			
	C/O IMMUNOGEN, INC.				3. Date of Earliest Transaction (Month/Day/Year) 06/16/2021							Officer below)		give title		specify	
(Street)	/ALTHAM MA 02451				4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3) 2. Tran				2. Transac Date (Month/Da	action 2A. Deemed Execution Date,		Code (In	4. Securities Acquired (A print of the control of t			Beneficia	es ally following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amount	(A) or (D) Price		Transact (Instr. 3 a	Transaction(s) (Instr. 3 and 4)			. ,	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	ive Conversion Date Execution Date, Trans y or Exercise (Month/Day/Year) if any Code		nsactio de (Inst	saction of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)			
				Co	de V	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares					
Deferred Share Unit	\$0 ⁽¹⁾	06/16/2021		A		15,000		(3)(2)		(2)	Common Stock ⁽²⁾	15,000	\$0 ⁽¹⁾	108,77	74	D	
Stock Option (right to buy)	\$6.77	06/16/2021		A		44,000		(4)	00	6/16/2031	Common Stock	44,000	\$6.77	44,00	0	D	

Explanation of Responses:

- 1. The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.
- 2. The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.
- 3. The deferred share units vest quarterly on each of 9/1/21, 12/1/21, 3/1/22, and 6/1/22, contingent upon the individual remaining a director as of each vesting date.
- $4. \ Exercisable \ as to \ 11,000 \ shares \ on \ each \ of \ 9/1/21, \ 12/1/21, \ 3/1/22, \ and \ 6/1/22, \ contingent \ upon \ the \ individual \ remaining \ a \ director \ as \ of \ each \ vesting \ date.$

/s/ Joseph J. Kenny, attorney in d6/17/2021

** Signature of Reporting Person Date

 $\label{lem:Remodel} \textbf{Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.}$

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.